To investigate whether 2-APB enhanced BZM treatment efficacy was correlated with autophagic activity suppression, the percentage of endogenous autophagic LC3-II puncta cells quantification was determined by immunofluorescence in H1975 and A549 NSCLC cells. The gene discussed is MAP1LC3A; the disease is non-small cell lung carcinoma.